Troax Group acquires Stommpy SpA

Troax Group, via its subsidiary Troax AB, has closed the acquisition of all shares in Italy’s Stommpy SpA (including Austrian subsidiary), a niche producer of flexible safety barriers with EUR 8m revenue in 2024 and strong positions in food & beverage and pharmaceuticals; Troax says Stommpy’s differentiated product set, Italian manufacturing and sales/installation capabilities will strengthen its Barrier offering. The deal was financed from Troax’s existing cash and credit facilities, transaction costs are expected to be immaterial and the acquisition is not expected to materially affect Troax’s EPS or net debt/EBITDA, reflecting that the purchase is strategically accretive but small versus Troax’s EUR 279m 2024 sales.

Analysis

Troax Group has completed the acquisition of all outstanding shares in Italy-based Stommpy SpA (including Austrian subsidiary Stommpy GmbH) effective 15 December 2025; Stommpy reported EUR 8m in revenue for 2024 and is positioned as a leading producer of flexible safety barriers in Italy with exports via distributors. Management states Stommpy brings unique, high‑quality products and in‑country manufacturing, sales and installation capabilities that strengthen Troax’s Barrier product line, citing particular strength in food & beverage and pharmaceutical end markets. The transaction is financed from Troax’s existing cash and credit facilities, transaction costs in Q4 are expected to be immaterial, and Troax does not expect a material impact on EPS or net debt/EBITDA. Market signals show a mildly positive tone and limited market impact; the deal is a small, strategic bolt‑on that offers operational upside through product differentiation and cross‑selling but carries typical integration and execution risk given its modest scale versus Troax’s EUR 279m 2024 sales.

Key Decisions for Investors

• Existing Troax shareholders should consider maintaining or modestly increasing positions because this is a strategic, low‑financial‑impact bolt‑on that expands the Barrier product line, while monitoring integration execution and cross‑sell progress
• Monitor upcoming quarterly reports for actual revenue contribution, margin profile from Stommpy and any deviations from management’s guidance that EPS and net debt/EBITDA will remain materially unchanged
• Event‑driven or M&A‑focused investors may consider small opportunistic exposure if the market underreacts to the strategic rationale, but limit position size until there is tangible evidence of commercial synergies in food & beverage and pharmaceutical segments